Investment in follow-on biologics may benefit Insmed, Momenta

03/27/2008 | Bloomberg1

The investment of Momenta Pharmaceuticals, Insmed and Cell Therapeutics in technology to develop duplicates of biotech drugs may pay off if Congress allows the sale of follow-on biologics in the U.S. Momenta is working with Novartis AG's Sandoz unit to make a version of Lovenox, Sanofi-Aventis SA's blood thinner, and three other biotech medicines. Cell Therapeutics is working on a technology to simplify production of gene-based drugs, while Insmed will begin human trials of two follow-on biotech treatments this year.

View Full Article in:

Bloomberg1

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA